BioCentury
ARTICLE | Clinical News

Tumor Necrosis Therapy regulatory update

February 14, 2000 8:00 AM UTC

TCLN received U.S. Patent No. 6,017,514 covering its TNT technology, which uses antibodies that bind to dead or decaying cells at the center of tumors, as a cancer imaging agent. ...